Session Chair Profile

CEO, Innovenn, Inc.

Ms. Drake brings over 20 years experience in the clinical research industry where she has managed successful cross-functional research teams and implemented development plans for multiple compounds, historically contributing to the development of 14 marketed compounds. In addition, Ms. Drake currently leads biomarker identification teams and facilitates cross-functional, cross-divisional collaborations to develop medical devices, including medical mobile devices that serve patients with rare diseases. In 2013, Ms. Drake founded her second company, Innovenn, Inc. Innovenn’s mission is to partner with advocacy organizations, pharmaceutical, biotechnology, and device companies to support the development of innovative diagnostic, prognostic, predictive, collaborative and preventive patient care solutions that complement new therapeutic advances.


“Beyond Therapeutics” for Patients with Rare Diseases
Pharmaceutical companies are redefining research objectives to go “Beyond Therapeutics”. Successful initiatives can include development of complementary mobile applications or decision support tools designed with patient input and interdisciplinary collaborations which facilitate broadened use of clinical research data.

Session Abstract – PMWC 2017 Silicon Valley

Session Synopsis: Rare Diseases are genetic, severe and life threatening; by definition they impact 200,000 patients or less. In 2015, 47% of the medications approved by the FDA were for rare diseases. We will explore how this trend has changed drug development: increasing collaboration, advancing personalized medications and personalized disease management tools.

Get Exclusive Access to the Top PMWC Talks

To receive the most comprehensive news and updates from the field of precision medicine, subscribe to the newsletter here.

Bonus for suscribing, you will get the access code for the top 3 talk videos from January's Precision Medicine World Conference.

You have successfully subscribed, you can access the talks here.